First-line treatment in metastatic colorectal cancer: Important or crucial?

被引：5
|
作者：
Malka, David [1 ]
Rotolo, Federico [2 ,3 ]
Boige, Valerie [1 ]
机构：
[1] Univ Paris Saclay, Dept Canc Med, Gustave Roussy, Villejuif, France
[2] Univ Paris Saclay, Serv Biostat & Epidemiol, Gustave Roussy, Villejuif, France
[3] Univ Paris Sud, Univ Paris Saclay, UVSQ, CESP,INSERM, Villejuif, France
来源：
EUROPEAN JOURNAL OF CANCER | 2017年 / 84卷
关键词：
PROGRESSION-FREE SURVIVAL; FOLFIRI PLUS CETUXIMAB; KRAS WILD-TYPE; EARLY TUMOR SHRINKAGE; PHASE-III; OPEN-LABEL; ACQUIRED-RESISTANCE; RANDOMIZED PHASE-3; 2ND-LINE TREATMENT; TREATMENT LINES;
D O I：
10.1016/j.ejca.2017.09.001
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：363 / 366
页数：4
相关论文
共 50 条
  • [31] Glasgow PrognosticScore as a Predictor of BevacizumabEfficacy in the First-line Treatment with Metastatic Colorectal Cancer
    Huang, Yuanyuan
    Li, Weiyu
    Quan, Qi
    Zhang, Bei
    Yang, Qiong
    JOURNAL OF CANCER, 2019, 10 (27): : 6858 - 6864
  • [32] First-Line Treatment of Metastatic Pancreatic Cancer
    Tokh, Mohammed
    Bathini, Venu
    Saif, Muhammad Wasif
    JOURNAL OF THE PANCREAS, 2012, 13 (02): : 159 - 162
  • [33] First-line treatment of metastatic breast cancer
    Trudeau, ME
    ANTI-CANCER DRUGS, 1996, 7 : 9 - 12
  • [34] First-line treatment of advanced colorectal cancer
    Hewish, Madeleine
    Cunningham, David
    LANCET, 2011, 377 (9783): : 2060 - 2062
  • [35] Irinotecan in the first-line treatment of colorectal cancer
    Saltz, LB
    ONCOLOGY-NEW YORK, 1998, 12 (08): : 54 - 58
  • [36] Safety and tolerability of first-line bevacizumab in metastatic colorectal cancer
    Akun, E.
    Okutur, K.
    Seber, S.
    Korkmaz, T.
    Aydin, K.
    Bozkurt, M.
    Namal, E.
    Hasbal, B.
    Tecimer, C.
    Demir, G.
    JOURNAL OF BUON, 2012, 17 (04): : 669 - 676
  • [37] Addition of Bevacizumab to First-Line Chemotherapy for Metastatic Colorectal Cancer
    Tsutsumi, Soichi
    Fujii, Takaaki
    Yamaguchi, Satoru
    Suto, Toshinaga
    Yajima, Reina
    Morita, Hiroki
    Kato, Toshihide
    Asao, Takayuki
    Kuwano, Hiroyuki
    HEPATO-GASTROENTEROLOGY, 2014, 61 (131) : 633 - 637
  • [38] Reply: Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer
    J Feliu
    J Barriuso
    British Journal of Cancer, 2011, 104 : 226 - 226
  • [39] Triplet combination of fluoropyrimidines, oxaliplatin, and irinotecan in the first-line treatment of metastatic colorectal cancer
    Masi, Gianluca
    Vasile, Enrico
    Loupakis, Fotios
    Bursi, Simona
    Ricci, Sergio
    Petrini, Iacopo
    Fontana, Andrea
    Allegrini, Giacomo
    Falcone, Alfredo
    CLINICAL COLORECTAL CANCER, 2008, 7 (01) : 7 - 14
  • [40] FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer
    Loupakis, F.
    Cremolini, C.
    Salvatore, L.
    Masi, G.
    Sensi, E.
    Schirripa, M.
    Michelucci, A.
    Pfanner, E.
    Brunetti, I.
    Lupi, C.
    Antoniotti, C.
    Bergamo, F.
    Lonardi, S.
    Zagonel, V.
    Simi, P.
    Fontanini, G.
    Falcone, A.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 (01) : 57 - 63
12345